期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 286, 期 1-2, 页码 99-103出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2009.05.028
关键词
Multiple sclerosis; Disease modifying treatment; Estrogen; Neuroprotection; Immunomodulation; Experimental autoimmune encephalomyelitis; Safety
资金
- NIAID NIH HHS [R01 AI050839, R01 AI050839-03, R01 AI050839-08] Funding Source: Medline
- NINDS NIH HHS [R01 NS045443-04, R01 NS051591-03, R01 NS045443, R01 NS051591, K24 NS062117-01, K24 NS062117] Funding Source: Medline
Currently available treatments for multiple sclerosis (MS) reduce inflammatory lesions on MRI and decrease clinical relapses but have limited effects on disability. Novel treatment options that target both the inflammatory as well as the neurodegenerative component of the disease are therefore needed. A growing body of evidence from basic science and clinical studies Supports the therapeutic potential of estrogens in MS. Mechanisms of action include both immunomodulatory and directly neuroprotective pathways. A first pilot trial of oral estriol treatment showed encouraging results. There are now several phase II trials underway to further determine the efficacy of estrogen treatment in MS. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据